Reaction

Eosinophilic Pneumonia reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,084 reports · 62 co-occurring drugs

As of the last recalculation, Eosinophilic Pneumonia appears in 3,084 FAERS reports alongside 62 co-occurring drug terms. The strongest observed disproportionality signal is DAPTOMYCIN (PRR 398.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Daptomycin	463	398.4	419.5
Rifampicin	60	40.8	41.0
Ciclesonide	72	36.5	36.7
Goserelin	64	32.8	33.0
Bicalutamide	55	24.8	24.9
Rifampin	47	22.0	22.1
Meropenem	77	16.6	16.6
Linezolid	67	15.5	15.5
Sodium Bicarbonate	51	15.0	15.1
Sodium Bicarbonate Injection,	51	15.0	15.1
Salmeterol Xinafoate	19	15.0	15.0
Piperacillin Sodium,Tazobactam Sodium	57	14.8	14.8
Amiodarone Hydrochloride	24	14.6	14.6
Piperacillin Sodium And Tazobactam Sodium	41	14.3	14.3
Cefepime	30	14.3	14.3
Cefepime Hydrochloride	32	13.5	13.6
Piperacillin And Tazobactam	25	13.3	13.3
Vancomycin Hydrochloride	109	11.5	11.6
Cholestyramine	20	11.2	11.2
Theophylline	19	11.2	11.2
Mesalamine	85	10.5	10.5
Naltrexone	47	10.4	10.4
Theophylline Anhydrous	19	10.4	10.4
Mepolizumab	74	10.3	10.3
Clarithromycin	51	10.2	10.2
Vancomycin	83	9.9	9.9
Levofloxacin	80	9.2	9.2
Levofloxacin In 5% Dextrose	80	9.2	9.2
Benralizumab	26	8.8	8.8
Ceftriaxone	42	8.7	8.8
Ceftriaxone Sodium	47	8.4	8.4
Minocycline	14	8.1	8.1
Calcium Gluconate	14	7.9	7.9
Dalteparin Sodium	11	7.0	7.0
Progesterone	22	6.5	6.5
Febuxostat Tablets 40 Mg	9	6.0	6.0
Febuxostat Tablets 80 Mg	9	6.0	6.0
Fluticasone Propionate And Salmeterol Xinafoate	52	5.9	5.9
Bleomycin Sulfate	9	5.9	5.9
Montelukast	70	5.7	5.7
Quinine	7	5.5	5.5
Amoxicillin And Clavulanate Potassium	22	5.5	5.5
Fluticasone Propionate Nasal	24	5.4	5.4
Enoxaparin Sodium	45	5.3	5.3
Gefitinib	7	5.2	5.2
Linagliptin	13	4.8	4.8
Norepinephrine	7	4.4	4.4
Fosaprepitant Dimeglumine	9	4.4	4.4
Abemaciclib	13	4.4	4.4
Dupilumab	258	3.9	3.9
Norepinephrine Bitartrate	8	3.8	3.8
Febuxostat	9	3.6	3.6
Osimertinib	17	3.6	3.6
Aprepitant	9	3.3	3.3
Brentuximab Vedotin	5	3.3	3.3
Brinzolamide	4	3.1	3.1
Bosutinib	4	3.0	3.0
Nivolumab	39	2.7	2.7
Ipilimumab	16	2.5	2.5
Apalutamide	4	2.3	2.3
Pembrolizumab	35	2.3	2.3
Durvalumab	6	2.0	2.0

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.